

CURRICULUM VITAE

Personal Status



Name: Ji-Youn Han

Present Address (at work):

Center for Lung Cancer, National Cancer Center

323 Ilsan-ro, Ilsandong-gu, Goyang-si, Gyeonggi-do, 10408,

South Korea

Tel : 82-31-920-1154

Fax : 82-31-920-2587

E-mail: jymama@ncc.re.kr

Educational Background

- | | |
|-----------|--|
| 1983-1989 | College of Medicine, the Catholic University of Korea
Graduated in February, 1989 with the M.D. degree |
| 1993-1995 | Post-Graduated School, College of Medicine,
the Catholic University of Korea
Awarded the degree of M.M.S. in Internal Medicine |
| 1995-1998 | Post-Graduated School, College of Medicine,
the Catholic University of Korea
Awarded the degree of Ph.D. in Internal Medicine |

Business Background

- | | |
|--------------------|---|
| Sep 2001-May-2007 | Senior Investigator, Lung Cancer Branch, National Cancer Center |
| Sep 2003-Aug 2004 | Visiting Assistant Professor, Department of Thoracic/Head and Neck Medical Oncology University of Texas M. D. Anderson Cancer Center, Houston, TX, U.S.A. |
| June 2007-Oct 2014 | Chief, Lung Cancer Branch, National Cancer Center |
| Aug 2010-Dec 2017 | Head, Lung Cancer Center, National Cancer Center |
| Aug 2012-Oct 2014 | Head, Division of Translational & Clinical Research I, National Cancer Center |
| Oct 2014-Mar 2016 | Head, Division of Convergence Technology, National Cancer Center |
| Oct 2015-Mar 2016 | Head, Cancer Genomics Branch, National Cancer Center |

Mar 2016-Mar 2019 Head, Division of Precision Medicine, National Cancer Center
Mar 2019-present Principal Scientist, Precision Medicine Branch, National Cancer Center
Dec 2016-Apr 2017 Member, Presidential Advisory Council on Science & Technology

Academic Activity

Korean association of Internal Medicine: active member (since 1994)
Korean Cancer Association: active member (since 1994)
International Association for the Study of Lung Cancer: active member (since 2001)
American Society of Clinical Oncology: active member (since 2002)
American Association for Cancer Research: active member (since 2002)

Major publications (during recent 5 years)

1. Kim HS, Lee JH, Nam SJ, Ock CY, Moon JW, Yoo CW, Lee GK, **Han JY**. Association of PD-L1 Expression with Tumor-Infiltrating Immune Cells and Mutation Burden in High-Grade Neuroendocrine Carcinoma of the Lung. J Thorac Oncol. 2018 Jan 31. pii: S1556-0864(18)30034-0. doi: 10.1016/j.jtho.2018.01.008. [Epub ahead of print]
2. Meulendijks D, Jacob W, Voest EE, Mau-Sorensen M, Martinez-Garcia M, Taus A, Fleitas T, Cervantes A, Lolkema MP, Langenberg MHG, De Jonge MJ, Sleijfer S, **Han JY**, Calles A, Felip E, Kim SW, Schellens JHM, Wilson S, Thomas M, Ceppi M, Meneses-Lorente G, James I, Vega-Harring S, Dua R, Nguyen M, Steiner L, Adessi C, Michielin F, Bossenmaier B, Weisser M, Lassen UN. Phase Ib Study of Lumretuzumab Plus Cetuximab or Erlotinib in Solid Tumor Patients and Evaluation of HER3 and Heregulin as Potential Biomarkers of Clinical Activity. Clin Cancer Res. 2017 Sep 15;23(18):5406-5415.
3. Lee Y, **Han JY**, Moon SH, Nam BH, Lim KY, Lee GK, Kim HT, Yun T, An HJ, Lee JS. Incorporating Erlotinib or Irinotecan Plus Cisplatin into Chemoradiotherapy for Stage III Non-small Cell Lung Cancer According to EGFR Mutation Status. Cancer Res Treat. 2017 Jan 6. doi: 10.4143/crt.2016.522. [Epub ahead of print]
4. Lee Y, Lee KH, Lee GK, Lee SH, Lim KY, Joo J, Go YJ, Lee JS, **Han JY**. Randomized Phase II Study of Afatinib Plus Simvastatin Versus Afatinib Alone in Previously Treated Patients with Advanced Non-Adenocarcinomatous Non-Small Cell Lung Cancer. Cancer Res Treat. 2017 Jan 13. doi: 10.4143/crt.2016.546. [Epub ahead of print]

5. **Han JY**, Lee GK, Lim KY, Lee YJ, Nam BH, Lee JS. ERCC1 Expression-Based Randomized Phase II Study of Gemcitabine/Cisplatin Versus Irinotecan/Cisplatin in Patients with Advanced Non-small Cell Lung Cancer. *Cancer Res Treat.* 2017 Jul;49(3):678-687.
6. Gadgeel SM, Shaw AT, Govindan R, Gandhi L, Socinski MA, Camidge DR, De Petris L, Kim DW, Chiappori A, Moro-Sibilot DL, Duruisseaux M, Crino L, De Pas T, Dansin E, Tessmer A, Yang JC, **Han JY**, Bordogna W, Golding S, Zeaiter A, Ou SI. Pooled Analysis of CNS Response to Alectinib in Two Studies of Pretreated Patients With ALK-Positive Non-Small-Cell Lung Cancer. *J Clin Oncol.* 2016 Dec;34(34):4079-4085.
7. Goss G, Tsai CM, Shepherd FA, Bazhenova L, Lee JS, Chang GC, Crino L, Satouchi M, Chu Q, Hida T, **Han JY**, Juan O, Dunphy F, Nishio M, Kang JH, Majem M, Mann H, Cantarini M, Ghiorghiu S, Mitsudomi T. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study. *Lancet Oncol.* 2016 Oct 14. pii: S1470-2045(16)30508-3.
8. Shin DH, Lee D, Hong DW, Hong SH, Hwang JA, Lee BI, You HJ, Lee GK, Kim IH, Lee YS, **Han JY**. Oncogenic function and clinical implications of SLC3A2-NRG1 fusion in invasive mucinous adenocarcinoma of the lung. *Oncotarget.* 2016 Sep 8. doi: 10.18632/oncotarget.11913. [Epub ahead of print]
9. **Han JY**, Choi JJ, Kim JY, Han YL, Lee GK. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer. *BMC Cancer.* 2016 Aug 12;16:627.
10. Lee H, Jeon S, Seo JS, Goh SH, **Han JY**, Cho Y. A novel strategy for highly efficient isolation and analysis of circulating tumor-specific cell-free DNA from lung cancer patients using a reusable conducting polymer nanostructure. *Biomaterials.* 2016 Sep;101:251-7.
11. **Han JY**, Lee KH, Kim SW, Min YJ, Cho E, Lee Y, Lee SH, Kim HY, Lee GK, Nam BH, Han H, Jung J, Lee JS. A Phase II Study of Poziotinib in Patients with Epidermal Growth Factor Receptor (EGFR)-Mutant Lung Adenocarcinoma who Have Acquired Resistance to EGFR-Tyrosine Kinase Inhibitors. *Cancer Res Treat.* 2016 May 3. doi: 10.4143/crt.2016.058. [Epub ahead of print]
12. **Han JY**, Kim HY, Lim KY, Hwangbo B, Lee JS. A phase II study of nintedanib in patients with relapsed small cell lung cancer. *Lung Cancer.* 2016 Jun;96:108-12.
13. Herbst RS, Baas P, Kim DW, Felip E, Pérez-Gracia JL, **Han JY**, Molina J, Kim JH, Arvis CD, Ahn MJ, Majem M, Fidler MJ, de Castro G Jr, Garrido M, Lubiniecki GM, Shentu Y, Im E, Dolled-Filhart M, Garon EB. Pembrolizumab versus docetaxel for

- previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. *Lancet*. 2016 Apr 9;387(10027):1540-50.
14. **Han JY** et al. Phase I/II study of gefitinib (Iressa®) and vorinostat (IVORI) in previously treated patients with advanced non-small cell lung cancer. *Cancer Chemother Pharmacol* 2015;75:475-83
 15. **Han JY**, Kim SH, Lee YS, Lee SY, Hwang JA, Kim JY, Yoon SJ, Lee GK. Comparison of targeted next-generation sequencing with conventional sequencing for predicting the responsiveness to epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) therapy in never-smokers with lung adenocarcinoma. *Lung Cancer*. 2014 Aug;85(2):161-7.
 16. **Han JY**, Lee YS, Kim BC, Lee GK, Lee S, Kim EH, Kim HM, Bhak J. Whole-genome analysis of a patient with early-stage small-cell lung cancer. *Pharmacogenomics J*. 2014 Dec;14(6):503-8.
 17. **Han JY** et al. Whole-genome analysis of a patient with early-stage small-cell lung cancer. *Pharmacogenomics J*. 2014;14:503-8
 18. **Han JY** et al. A genome-wide association study of survival in small-cell lung cancer patients treated with irinotecan plus cisplatin chemotherapy. *Pharmacogenomics J*. 2014 Feb;14(1):20-7
 19. **Han JY** et al. A phase II study of sunitinib in patients with relapsed or refractory small cell lung cancer. *Lung Cancer*. 2013 Feb;79(2):137-42.
 20. **Han JY** et al. A randomized phase II study of irinotecan plus cisplatin versus irinotecan plus capecitabine with or without isosorbide-5-mononitrate in advanced non-small-cell lung cancer. *Ann Oncol*. 2012 Nov;23(11):2925-30.
 21. **Han JY** et al. First-SIGNAL: first-line single-agent iressa versus gemcitabine and cisplatin trial in never-smokers with adenocarcinoma of the lung. *J Clin Oncol*. 2012 Apr 1;30(10):1122-8